Hydroxystilbamidine

Summary

Hydroxystilbamidine (CHEMBL1301) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 280.32 Da · C16H16N4O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1301
Name	Hydroxystilbamidine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5284571
Molecular formula	C16H16N4O
Molecular weight	280.32
InChIKey	TUESWZZJYCLFNL-DAFODLJHSA-N

SMILES: C1=CC(=CC=C1/C=C/C2=C(C=C(C=C2)C(=N)N)O)C(=N)N

IUPAC name: 4-[(E)-2-(4-carbamimidoylphenyl)ethenyl]-3-hydroxybenzenecarboximidamide

Also known as: Hidroxiestilbamidina, Hydroxystilbamidine, SID29218047, SID124893257, HYDROXYSTILBAMIDINE, hydroxystilbamidine

Parent form; salt/anhydrous children: CHEMBL1200847, CHEMBL2023895

Patent coverage: 794 distinct patent families (2,961 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 2,960 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).